Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zemplar in birch pollen allergic rhinitis/rhinoconjunctivitis
2015-003202-16Phase 2Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of paricalcitol in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: IL-10 production after 4 weeks of treatment. Started Aug 2015; status: active.
02
Drugs
paricalcitol
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2015-003202-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003202-16.